Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Biopharmaceuticals company Biocon has secured approval from the Drugs Controller General of India (DCGI) for its plaque psoriasis drug Itolizumab (ALZUMAb) for emergency use in Covid-19 patients.
The approval is for 25mg / 5ml injection solution of the medicine to treat cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients with Covid-19.
Itolizumab is said to be the first new biologic therapy approved globally for the treatment of moderate to severe Covid-19 complications.